November 29, 2016 07:57 AM EST
People
Pharma

Stub­born Acte­lion CEO Clozel spurs shift in buy­out talks, but J&J coun­ters with a raised bid -- re­ports

John Carroll

Editor & Founder

Acte­lion was nev­er go­ing to be an ea­ger part­ner in any takeover at­tempt. The Swiss biotech’s CEO, Jean-Paul Clozel, has stub­born­ly re­sist­ed ear­li­er at­tempts to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times